Expression of MK-1 and RegIV and its clinicopathological significances in the benign and malignant lesions of gallbladder

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Yang, Leping ^a,b   Lan, Sigen ^a   Liu, Jieqiong ^a   Yang, Zhulin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic cholecystitis; Gallbladder neoplasms; Gallbladder polyp; Immunohistochemistry; Mk 1; Regenerating gene IV; Tumor associated antigen

Indexed keywords

CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; LECTIN; REG4 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADENOMATOUS POLYP; ARTICLE; BIOSYNTHESIS; CANCER STAGING; CHOLECYSTITIS; CHRONIC DISEASE; FEMALE; GALLBLADDER TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; ADENOMATOUS POLYPS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CHOLECYSTITIS; CHRONIC DISEASE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LECTINS, C-TYPE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054741229     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-100     Document Type: Article

References (16)

1. Abe H, Kuroki M, Imakiire T, Yamauchi Y, Yamada H, Arakawa F. Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. J Immunol Methods 2002, 270(2):227-33. 10.1016/S0022-1759(02)00332-0, 12379327.
2. Deveci MS, Deveci G. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007, 10(2):112-6. 10.1007/s10120-007-0418-7, 17577621.
3. El-Meghawry El-Kenawy A, El-kott AF, Hamed SM, Kuroki M. Prognostic value of carcinoma-associated antigen MK-1 in urinary bladder carcinoma. Int J Biol Markers 2006, 21(3):170-4.
4. Ikeda T, Nakayama Y, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Yamashita Y, Kuroki M, Ikeda S. FU-MK-1 expression in human gallbladder carcinoma: an antigenic prediction marker for a better postsurgical prognosis. American journal of clinical pathology 2009, 132(1):111-7. 10.1309/AJCP5HPHG6NGBWZO, 19864241.
5. Hamada Y, Nakayama Y, Mizoguchi M, Ikeda S, Kuroki M, Iwasaki H. MK-1 expression in carcinoma of the ampulla of Vater as a predictor of improved prognosis after surgical resection. Cancer letters 2006, 243(2):211-6. 10.1016/j.canlet.2005.11.037, 16616808.
6. Yamagishi H, Fukui H, Sekikawa A, Kono T, Fujii S, Ichikawa K, Tomita S, Imura J, Hiraishi H, Chiba T, Fujimori T. Expression profile of REG family proteins REG Ialpha and REG IV in advanced gastric cancer: comparison with mucin phenotype and prognostic markers. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2009, 22(7):906-13.
7. Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, Shimomoto T, Fujii K, Ohmori H, Yasui W. Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif 2009, 42(1):110-21. 10.1111/j.1365-2184.2008.00577.x, 19143768.
8. Bishnupuri KS, Luo Q, Korzenik JR, Henderson JO, Houchen CW, Anant S, Dieckgraefe BK. Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther 2006, 5(12):1714-20. 10.4161/cbt.5.12.3469, 17106246.
9. Pankova-Kholmyansky I, Arber N. Reg IV can serve for early diagnosis and therapy. Cancer Biol Ther 2007, 6(1):123-4. 10.4161/cbt.6.1.3846, 17297304.
10. Hayashi T, Matsubara A, Ohara S, Mita K, Hasegawa Y, Usui T, Arihiro K, Norimura S, Sentani K, Oue N, Yasui W. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep 2009, 21(1):95-100.
11. Sasahira T, Oue N, Kirita T, Luo Y, Bhawal UK, Fujii K, Yasui W, Kuniyasu H. Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology 2008, 53(6):667-75. 10.1111/j.1365-2559.2008.03188.x, 19076683.
12. Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am 2010, 39(2):331-42. x, 10.1016/j.gtc.2010.02.006, 20478489.
13. Leonardo E, Valente G, Cappia S, Cianfriglia M, Arancia G, Meschini S, Scagliotti GV. Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994, 57(6):841-6. 10.1002/ijc.2910570613, 7911456.
14. Dowling GP, Kelly JK. The histogenesis of adenocarcinoma of the gallbladder. Cancer 1986, 58(8):1702-8. 10.1002/1097-0142(19861015)58:8<1702::AID-CNCR2820580821>3.0.CO;2-Z, 3756792.
15. Khalid H, Yasunaga A, Kishikawa M, Shibata S. Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors. Cancer 1995, 75(10):2571-8. 10.1002/1097-0142(19950515)75:10<2571::AID-CNCR2820751026>3.0.CO;2-U, 7736403.
16. Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 2006, 97(11):1191-7. 10.1111/j.1349-7006.2006.00297.x, 16918991.